These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1933 related items for PubMed ID: 19289266

  • 1. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):16-22. PubMed ID: 19289266
    [Abstract] [Full Text] [Related]

  • 2. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
    Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2010 Aug 01; 77(5):1315-21. PubMed ID: 20044216
    [Abstract] [Full Text] [Related]

  • 3. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 5. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 6. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):600-7. PubMed ID: 21985944
    [Abstract] [Full Text] [Related]

  • 7. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 8. Impact of race on biochemical disease recurrence after prostate brachytherapy.
    Yamoah K, Stone N, Stock R.
    Cancer; 2011 Dec 15; 117(24):5589-600. PubMed ID: 21692058
    [Abstract] [Full Text] [Related]

  • 9. Combined modality treatment in the management of high-risk prostate cancer.
    Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1352-9. PubMed ID: 15275720
    [Abstract] [Full Text] [Related]

  • 10. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

  • 11. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF, Nelson JW, Alkaissi AK, Das S, Clough RW, Broadwater G, Anscher MS, Chino JP, Oleson JR.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):139-46. PubMed ID: 19836161
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.
    Seung SK, Kroll S, Wilder RB, Posner MD, Roach M.
    Cancer J Sci Am; 1998 May 01; 4(3):168-74. PubMed ID: 9612598
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 97.